1,3-Benzodioxolylbutanamine
Entactogen drug
From Wikipedia, the free encyclopedia
1,3-Benzodioxolylbutanamine (BDB), also known as 3,4-methylenedioxy-α-ethylphenethylamine or as J, is an entactogen of the phenethylamine, phenylisobutylamine, and MDxx families related to MDMA.[1][2]
- DE: Anlage I (Authorized scientific use only)
- UK: Class A
- US: Analogue to a Schedule I/II drug
| |
 | |
| Clinical data | |
|---|---|
| Other names | BDB; MDB; J; 3,4-Methylenedioxy-α-ethylphenethylamine; MDAEPEA; Benzodioxolylbutanamine; 3,4-Methylenedioxybutanphenamine |
| Routes of administration | Oral[1] |
| Drug class | Serotoninânorepinephrine releasing agent; Entactogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO2 |
| Molar mass | 193.246 g·molâ1 |
| 3D model (JSmol) | |
| Melting point | 159 to 161 °C (318 to 322 °F) |
| |
| |
| (verify) | |
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists BDB's dose as 150 to 230 mg orally and its duration as 4 to 8 hours.[1] BDB produces entactogenic, MDMA-like effects.[1] Although pleasant and euphoric, BDB is also fairly sedating, and some users feel that the lack of stimulant effect makes it less enjoyable than other similar drugs.[1] Additional side effects associated with BDB include nystagmus and dizziness.[1]
Interactions
Pharmacology
Pharmacodynamics
Receptor and transporter interaction data have been reported for BDB.[3][4] It acts as a serotoninânorepinephrine releasing agent (SNDRA) with only weak effects on dopamine.[4] Animal studies and anecdotal reports have found that BDB is a slightly more potent serotonin releasing agent than its methylated sister compound methylbenzodioxylbutanamine (MBDB; "Eden", "Methyl-J").[5]
Chemistry
BDB, also known as 1,3-benzodioxolylbutanamine or as 3,4-methylenedioxy-α-ethylphenethylamine, is a phenethylamine, α-ethylphenethylamine (phenylisobutylamine), and methylenedioxyphenethylamine (MDxx) related to MDMA.[1] It is the α-ethyl analogue of 3,4-methylenedioxyphenethylamine (MDPEA) and 3,4-methylenedioxyamphetamine (MDA) and the 3,4-methylenedioxy derivative of α-ethylphenethylamine (AEPEA).[1]
Synthesis
The chemical synthesis of BDB has been described.[1]
Analogues
Analogues of BDB include MBDB (methyl-J), EBDB (ethyl-J), 1,3-benzodioxolylpentanamine (BDP; K), MBDP (methyl-K), EBDP (ethyl-K), and MPAP (PDBP; propyl-K), among others.[1]
History
BDB was first described in the scientific literature by at least 1973.[6]
Society and culture
Recreational use
Rather than as a recreational drug itself, BDB is more commonly known as a metabolite of the N-alkylated analogues MBDB and ethylbenzodioxylbutanamine (EBDB; "Ethyl-J"), which have appeared in MDMA or "ecstasy" tablets.[7][8] Although BDB itself has not been reported as being sold as "ecstasy", urine analysis of users suggest that this drug may have appeared as a street drug, though it is unclear whether the positive urine test for BDB resulted from consumption of BDB itself or merely as a metabolite of MBDB.[9]